James Crowley: Precision Cancer Therapy Advances
James Crowley, Professor of Medicine Emeritus at Brown University, Captain at U.S. Navy Reserve, shared a post on LinkedIn about a recent article by Beilei Liu et al. published in Signal Transduction and Targeted Therapy Journal:
“Emerging as the most fervently pursued research modalities are small molecule targeted agents including lipid nanoparticles, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy.
The successful application of CAR-T cell therapy by Carl June in 2011 and the FDA approval of Pembrolizumab and Nivolumab in 2014 for melanoma treatment highlighted the potential of cancer immunotherapy.
Preventive measures also evolved, as evidenced by the approval of the nine-valent Gardasil 9 vaccine, offering broader protection against HPV strains linked to cervical cancer.
In summary, much recent research has shown that gut microbiota is closely related to the occurrence and progression of tumors, as well as response to a variety of cancer therapies.
It is clear that studies on gut microbiota are essential for the prevention and treatment of cancer.
Overall, the future of precision cancer treatment will be diversified and integrated, combining traditional therapeutic methods with emerging technologies to offer patients a wider range of treatment choices.
These cutting-edge treatment modalities not only afford personalized and precise tumor targeting, but also provide patients with enhanced therapeutic comfort but the potential to impede disease progression.
The advantages, disadvantages, challenges, and representative drugs or clinical trials related to cancer treatments discussed herein are compiled in Table 7 which offers a comprehensive overview and comparison.”
Title: Exploring treatment options in cancer: tumor treatment strategies
Authors: Beilei Liu, Hongyu Zhou, Licheng Tan, Kin To Hugo Siu, Xin-Yuan Guan
Read the Full Article on Signal Transduction and Targeted Therapy Journal
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers